Analysis of U.S. Patent 11,084,780: Therapeutic Antibodies for Treating Autoimmune Diseases
U.S. Patent 11,084,780, granted on August 10, 2021, to Bristol-Myers Squibb Company, covers specific therapeutic antibodies and their use in treating autoimmune diseases. The patent's claims focus on antibodies targeting the IL-23 receptor (IL-23R) and methods of administration for conditions such as psoriasis, psoriatic arthritis, and Crohn's disease. The patent landscape surrounding IL-23R inhibitors is highly competitive, with multiple pharmaceutical companies holding key patents and facing potential litigation.
What are the core claims of U.S. Patent 11,084,780?
The patent's primary claims define specific amino acid sequences for human antibodies that bind to the IL-23R. Claim 1, for example, describes an isolated antibody that binds to human IL-23R and comprises a heavy chain variable region with specific CDR (complementarity-determining region) sequences. Similar claims detail the light chain variable regions of these antibodies.
- Claim 1: Defines an isolated antibody that binds to human IL-23R and comprises a heavy chain variable region and a light chain variable region, where the heavy chain variable region comprises SEQ ID NO: 1, and the light chain variable region comprises SEQ ID NO: 2.
- Claim 14: Claims a pharmaceutical composition comprising the antibody of Claim 1 and a pharmaceutically acceptable carrier.
- Claim 21: Claims a method of treating a subject suffering from a condition mediated by IL-23, comprising administering a therapeutically effective amount of the antibody of Claim 1. The conditions specified include psoriasis, psoriatic arthritis, inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis.
The claims are characterized by their specificity regarding the amino acid sequences of the antibody's variable regions, which are crucial for determining antigen binding and therapeutic efficacy. This specificity aims to provide broad protection against direct infringement by entities developing antibodies with similar structural and functional characteristics.
What is the biological target of the patented antibodies?
The antibodies described in U.S. Patent 11,084,780 target the interleukin-23 receptor (IL-23R). IL-23 is a cytokine that plays a significant role in the immune system, particularly in regulating T-cell differentiation and function. It is a heterodimeric receptor composed of a p19 subunit and an IL-12Rβ1 subunit.
IL-23 signaling is implicated in the pathogenesis of several chronic inflammatory and autoimmune diseases. By blocking the binding of IL-23 to its receptor, the antibodies disclosed in this patent aim to inhibit downstream signaling pathways that promote inflammation.
- IL-23 Pathway Involvement: The IL-23 pathway is known to promote the differentiation of T helper 17 (Th17) cells and the production of pro-inflammatory cytokines like IL-17 and IL-22.
- Disease Relevance: Dysregulation of this pathway is associated with conditions such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
- Therapeutic Rationale: Inhibition of IL-23 signaling through targeting IL-23R is a validated strategy for reducing inflammation in these diseases.
What autoimmune diseases are covered by the patent?
The patent explicitly lists several autoimmune and inflammatory diseases for which the claimed antibodies are intended to be used. These indications represent significant therapeutic markets.
- Psoriasis
- Psoriatic arthritis
- Inflammatory bowel disease (IBD)
- Crohn's disease
- Ulcerative colitis
The selection of these diseases aligns with the known role of IL-23 in their pathogenesis. The patent claims methods of treatment for subjects suffering from these conditions, covering both prophylactic and therapeutic applications.
What is the patent landscape for IL-23R inhibitors?
The patent landscape for IL-23R inhibitors is highly active and competitive. Several major pharmaceutical companies have invested heavily in developing antibodies targeting this pathway, leading to a complex web of intellectual property. Bristol-Myers Squibb, with its U.S. Patent 11,084,780, is a key player. However, other entities hold significant patents covering different IL-23R antibodies or related technologies.
Key competitors and their relevant patent strategies include:
- Janssen (Johnson & Johnson): Known for its IL-23 inhibitor Stelara (ustekinumab), which targets both IL-12 and IL-23. Janssen also holds patents on antibodies specifically targeting IL-23, such as guselkumab.
- AbbVie: Developing IL-23 inhibitors, including risankizumab, which has demonstrated efficacy in psoriasis and psoriatic arthritis. AbbVie holds patents covering its proprietary IL-23 antibodies.
- Eli Lilly and Company: Has also been active in this therapeutic area, with research programs focused on IL-23 inhibitors.
- Takeda Pharmaceutical Company: Has a portfolio of immunology drugs, including those targeting cytokine pathways relevant to autoimmune diseases.
The presence of multiple patents covering distinct antibodies, even if they target the same receptor, can lead to:
- Patent Thickets: A dense network of overlapping intellectual property rights that can make it difficult for new entrants to operate without infringing.
- Interference Proceedings: Patent offices may conduct proceedings to determine priority of invention between competing patent applications.
- Litigation: Companies often engage in patent litigation to defend their market exclusivity or to challenge competitors' patents.
Comparison of Patent Strategies:
| Company |
Key IL-23/IL-23R Inhibitor(s) |
Primary Patent Strategy |
| Bristol-Myers Squibb |
Antibodies claimed in 11,084,780 |
Specific antibody sequences and methods of use. |
| Janssen |
Stelara, Tremfya (guselkumab) |
Broad claims covering antibody classes and specific antibodies, as well as use patents. |
| AbbVie |
Skyrizi (risankizumab) |
Focus on antibody sequences, binding characteristics, and therapeutic indications. |
The scope and strength of patents like U.S. Patent 11,084,780 are critical for market exclusivity and for fending off biosimilar or generic competition once the patent expires.
What is the therapeutic significance of targeting IL-23R?
Targeting the IL-23 receptor is a validated and effective therapeutic strategy for several chronic inflammatory and autoimmune conditions. The IL-23 cytokine and its receptor play a pivotal role in the immune response, particularly in the amplification of inflammatory processes mediated by Th17 cells.
-
Mechanism of Action: By blocking IL-23R, these antibodies disrupt the IL-23 signaling pathway, which is responsible for:
- Promoting the differentiation and survival of Th17 cells.
- Stimulating the production of pro-inflammatory cytokines such as IL-17A, IL-17F, and IL-22.
- Inducing the recruitment of inflammatory cells to affected tissues.
-
Clinical Efficacy: Inhibition of IL-23 signaling has led to significant clinical improvements in patients with:
- Psoriasis: Reduced skin inflammation, erythema, and plaque thickness.
- Psoriatic Arthritis: Alleviation of joint pain, swelling, and radiographic progression.
- Crohn's Disease and Ulcerative Colitis: Induction and maintenance of remission, healing of the intestinal lining, and reduction in symptoms.
The therapeutic success of existing IL-23 inhibitors underscores the importance of the IL-23 pathway as a target for drug development. U.S. Patent 11,084,780 contributes to this by claiming specific antibody constructs designed to effectively and selectively inhibit this pathway.
What are potential challenges and future outlooks for IL-23R patents?
The patent landscape for IL-23R inhibitors presents several challenges and uncertainties for stakeholders. Patent validity, scope, and potential for infringement are critical considerations.
- Patent Validity: Patents can be challenged in court or through post-grant review proceedings at the U.S. Patent and Trademark Office (USPTO) based on prior art or inventorship issues.
- Infringement Analysis: Determining whether a competitor's product infringes a patent requires a detailed comparison of the patented claims with the competitor's product, considering both literal infringement and the doctrine of equivalents.
- Biosimilar Competition: As patents for first-generation IL-23 inhibitors expire, biosimilar versions may enter the market, increasing competition and potentially reducing market share for the innovator products. However, the complexity of biologic manufacturing and patent protection around specific antibody sequences can delay biosimilar entry.
- Evolving Science: New research may uncover alternative therapeutic targets or pathways that could diminish the market dominance of current IL-23 inhibitors.
- Exclusivity Periods: The term of a U.S. patent is generally 20 years from the filing date, but various extensions, such as those under the Hatch-Waxman Act for pharmaceuticals, can extend market exclusivity. For biological products, the Biologics Price Competition and Innovation Act (BPCIA) provides a 12-year data exclusivity period.
The future outlook for IL-23R patents, including U.S. Patent 11,084,780, depends on the strength and enforceability of the claims, the ongoing competitive landscape, and the continued clinical relevance of IL-23 inhibition in treating autoimmune diseases. Companies holding these patents will need to actively monitor the market for potential infringements and defend their intellectual property.
Key Takeaways
- U.S. Patent 11,084,780 grants Bristol-Myers Squibb exclusive rights to specific therapeutic antibodies targeting the IL-23 receptor (IL-23R).
- The patent claims define antibodies by their precise amino acid sequences in the heavy and light chain variable regions.
- The patented antibodies are indicated for treating autoimmune diseases including psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
- The IL-23R pathway is a validated therapeutic target, with inhibitors demonstrating significant clinical efficacy in inflammatory conditions.
- The IL-23R inhibitor patent landscape is highly competitive, featuring multiple pharmaceutical companies with overlapping intellectual property.
- Challenges include patent validity, infringement analysis, and the eventual advent of biosimilar competition.
Frequently Asked Questions
-
When was U.S. Patent 11,084,780 granted?
U.S. Patent 11,084,780 was granted on August 10, 2021.
-
What is the primary biological target of the antibodies described in this patent?
The primary biological target is the interleukin-23 receptor (IL-23R).
-
Which specific autoimmune diseases are mentioned in the patent as indications for treatment?
The patent mentions psoriasis, psoriatic arthritis, inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis.
-
Who is the assignee of U.S. Patent 11,084,780?
The assignee is Bristol-Myers Squibb Company.
-
Does this patent cover methods of administration or only the antibody molecules themselves?
The patent covers both specific antibody molecules (claims focused on structure) and methods of treating specific diseases by administering these antibodies (method of use claims).
Citations
[1] Bristol-Myers Squibb Company. (2021). Therapeutic antibodies for treating autoimmune diseases (U.S. Patent No. 11,084,780). Washington, DC: U.S. Patent and Trademark Office.
